Estrone and estradiol are both estrogens with estrone being the less potent form and estradiol being the most potent estrogen. The binding of the latter to cellular regulatory elements stimulates the proliferation of breast cancer cells. A high ratio of estradiol/estrone is related to increased cell proliferation, and is of great importance to understanding of breast cancer mechanisms. 17beta-hydroxysteroid dehydrogenase type 1 and type 2 play important roles in the activation of estrone and inactivation of estradiol. Breast cancer cells T47D, MCF-7, BT 20, and JEG 3 as control cells, were chosen to evaluate the contribution of these two enzymes to the ratio. Twenty four hours after addition of different concentrations of estrone and estradiol, the ratio stabilized to around 9/1 in breast cancer cell lines with high expression of type 1 (T47D, BT 20, and JEG 3), whereas it approached 1/5 in cells with low expression of type 1 (MCF-7). The estradiol/estrone concentration ratio was modified to 9/1 in MCF-7 and HEK-293 cells over-expressing type 1. In T47D and BT 20, this ratio was decreased from 9/1 to nearly 1/5 (19/81 and 17/83 respectively) after type 1 knockdown by specific siRNAs. Type 2 is mainly involved in the conversion of estradiol into estrone. This ratio was decreased from 9/1 to 7/3 after over-expression of type 2 in MCF-7 cells already over-expressing type 1. The ratio was further decreased by the addition of the oxidative cofactor, NAD, to the cell culture to facilitate the estradiol to estrone conversion catalyzed by type 2. These results demonstrate that the estradiol/estrone ratio is controlled by both type 1 and type 2 with an additional contribution by NAD, although type 1 is the first determining factor in the cellular environment compared with type 2 and cofactors. Moreover, kinetic studies were carried out in intact cells as a new approach, using HEK-293 cells over-expressing type 1 and T47D breast cancer cells.
References
[1]
Lin SX, Chen J, Mazumdar M, Poirier D, Wang C, et al. (2010) Molecular therapy of breast cancer: progress and future directions. Nat Rev Endocrinol 6(9): 485–493.
[2]
American Cancer Society. What are the key statistics about lung cancer (online), available:http://www.cancer.org/docroot/cri/conten？t/cri_2_4_1x_what_are_the_key_Statistics？_about_lung_cancer_15. asp, accessed 2009 Dec 5.
[3]
American Cancer Society. Breast cancer facts and figures 2009–2010 (online), available: http://www.cancer.org/downloads/STT/F861？009_final%209-08-09.pdf., accessed 2009 Dec 5.
[4]
Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, et al. (2005) Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 12(4): 701–720.
[5]
Fox EM, Andrade J, Shupnik MA (2009) Novel actions of estrogen to promote proliferation: Integration of cytoplasmic and nuclear pathways. Steroids 74(7): 622–627.
[6]
Gunnarsson C, Olsson BM, St？l O (2001) Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res 61(23): 8448–8451.
[7]
Aka JA, Mazumdar M, Chen CQ, Poirier D, Lin SX (2010) 17β-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Mol Endocrinol 24(4): 832–845.
[8]
Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, et al. (2001) Involvement of up-regulation of 17β-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 94(5): 685–689.
[9]
Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L, et al. (2009) Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients. Clin Cancer Res 15(10): 3610–3616.
[10]
Meier M, M？ller G, Adamski J (2009) Perspectives in understanding the role of human 17β-hydroxysteroid dehydrogenases in health and disease. Ann N Y Acad Sci 1155(1): 15–24.
Jansson A (2009) 17beta-hydroxysteroid dehydrogenase enzymes and breast cancer. J Steroid Biochem Mol Biol 114(1–2): 64–67.
[13]
Peltoketo H, Luu-The V, Simard J, Adamski J (1999) 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol 23(1): 1–11.
[14]
Jin JZ, Lin SX (1999) Human estrogenic 17beta-hydroxysteroid dehydrogenase: predominance of estrone reduction and its induction by NADPH. Biochem Biophys Res Commun 259(2): 489–493.
[15]
Lu ML, Huang YW, Lin SX (2002) Purification, reconstitution, and steady-state kinetics of the trans-membrane 17beta -hydroxysteroid dehydrogenase 2. J Biol Chem 277(25): 22123–22130.
[16]
Sherbet DP, Guryev OL, Papari-Zareei M, Mizrachi D, Rambally S, et al. (2009) Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17beta-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 Cells. Endocrinology 150(9): 4154–4162.
[17]
Miettinen MM, Mustonen MV, Poutanen MH, Isomaa VV, Vihko RK (1996) Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J 314: 839–845.
[18]
Laplante Y, Rancourt C, Poirier D (2009) Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors. Mol Cell Endocrinol 301(1–2): 146–153.
[19]
Jansson A, Gunnarsson C, St？l O (2006) Proliferative responses to altered 17beta-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors. Endocr Relat Cancer 13(3): 875–884.
[20]
Khan N, Sharma KK, Andersson S, Auchus RJ (2004) Human 17beta-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells. Arch Biochem Biophys 429(1): 50–59.
[21]
Illig T, Gieger C, Zhai GJ, Margl WR, Sattler RW, et al. (2010) A genome-wide perspective of genetic variation in human metabolism. Nat Genet 42(2): 137–141.
[22]
Smuc T, Rizner TL (2009) Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines. Chem Biol Interact 178(1–3): 228–233.
[23]
Gangloff A, Garneau A, Huang YW, Yang F, Lin SX (2001) Human oestrogenic 17beta-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction. Biochem J 356: 269–276.
[24]
Pasqualini JR, Chetrite G, Nguyen BL, Maloche C, Delalonde L, et al. (1995) Estrone sulfate-sulfatase and 17[beta]-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol 53(1–6): 407–412.
[25]
Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, et al. (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81(4): 1460–1464.
[26]
Castoria G, Migliaccio A, Giovannelli P, Auricchio F (2010) Cell proliferation regulated by estradiol receptor: Therapeutic implications. Steroids 75(8–9): 524–527.
[27]
Laganière J, Deblois G, Lefebvre C, Bataille AR, Robert F (2005) From the cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA 102(33): 11651–11656.
[28]
Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB (2004) Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of Cyclin D1 to its own gene promoter. Mol Cell Biol 24(16): 7260–7274.
[29]
Peltoketo H, Isomaa V, M？entausta O, Vihko R (1988) Complete amino acid sequence of human placental 17beta-hydroxysteroid dehydrogenase deduced from cDNA. FEBS Letters 239(1): 73–77.
[30]
Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, et al. (1993) Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J Biol Chem 268(17): 12964–12969.
[31]
Aka JA, Mazumdar M, Lin SX (2009) Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: Critical in the cell proliferation of breast cancer. Mol Cell Endocrinol 301(1–2): 183–190.
